During severe COVID-19 disease, activated CD4+ T cells reactive to SARS-CoV-2 C-terminal S and NCAP were also detectable and frequencies of activated, reactive T cells were generally much higher (1.8–2.2% CD154+CD137+CD4+ during COVID-19) (Supplementary Table 1). This evidence concerns the gene TNFRSF9 and COVID-19.